Joanne Palmisano

TL;DR: Among patients with ACS, the early initiation of an aggressive simvastatin regimen resulted in a favorable trend toward reduction of major cardiovascular events and the trial did not achieve the prespecified end point.

TL;DR: Combination therapy with simvastatin 20 mg and fenofibrate 160 mg in patients with combined hyperlipidemia resulted in additional improvement in all lipoprotein parameters measured compared with simVastatin20 mg monotherapy and was well tolerated, and this combination therapy is a beneficial therapeutic option for managing combined hyper Lipidemia.

TL;DR: Across multiple subgroups, ezetimibe added to statin therapy consistently produced significant additional improvements in LDL-C levels and goal attainment, as well as in other lipoproteins, compared with addition of placebo.

TL;DR: Ezetimibe/simVastatin was more effective than atorvastatin in lowering LDL-C at each dose comparison and provided greater increases in HDL-C in statin doses at the 40- and 80-mg statin dose.

TL;DR: In patients receiving tirofiban and aspirin, enoxaparin is a suitable alternative to unfractionated heparin for treatment of non-ST-elevation ACS and is consistent with prior trials performed without the use of glycoprotein IIb/IIIa inhibitors.